With new Omi­cron da­ta, Ada­gio halts tri­als for vaunt­ed Covid an­ti­body but sees a path ahead

Last month, Ada­gio shares tanked af­ter re­port­ing its Covid-19 an­ti­body saw a 300-fold re­duc­tion in its abil­i­ty to neu­tral­ize the Omi­cron vari­ant. But late Wednes­day …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER